# **A**CQUISDATA

NO.: 29053

#### Follow us on :



### Contents

- · News and Commentary
- Media Releases
- Latest Research
- The Industry
- Leading Companies in the Industry

## Industry SnapShots

Up to date business intelligence reports covering developments in the world's fastest growing industries

## AUSTRALIA BIOTECHNOLOGY AND PHARMACEUTICALS

#### 26 October 2021

#### This Week's News

• Mirage News - Australia's biggest week in biotech begins - 26/10/2021

More than 900 Australian and global life science leaders are uniting virtually this week to celebrate, champion, and further the sector at AusBiotech 2021 and Australia Biotech Invest & Partnering 2021, Australia's premier life science conferences, commenced today.

- For the complete story, see: https://www.miragenews.com/australias-biggest-week-in-biotech-begins-659380/
- OpenGov Asia The Philippines and Australia Collaborate to Boost Agricultural Research
   25/10/2021

In a statement, DOST-PCAARRD said it and ACIAR will continue to collaborate and explore new approaches to deliver agricultural research for development in the Philippines and the region for many years to come.

For the complete story, see: https://opengovasia.com/the-philippines-and-australia-collaborate-to-boost-agricultural-research/

ABC News - New breast cancer drug and IVF screening listed on the PBS - 24/10/2021
 A drug used to treat late-stage metastatic breast cancer, as well as a new screening tool for IVF eggs.

For the complete story, see: https://www.abc.net.au/news/2021-10-24/new-breast-cancer-drug-and-ivf-screening-listed-on-pbs/13600990

#### **Other Stories**

- The Age NSW to fund RNA pilot facility to develop drugs and vaccines 21/10/2021
- WAFB GenFleet Announces First Patient Dosed in Phase Ib/II Trial of TGF-β R1 Inhibitor in Combination with PD-1 Inhibitor in Global Multi-center Research - 20/10/2021
- Mint More than 300 covid-19 vaccines are being developed 19/10/2021
- The Guardian TGA dismisses bid to make contraceptive pill available over the counter in Australia - 18/10/2021
- Lexology Patent term extensions in Australia What if the patent covers more than one approved product? - 17/10/2021

#### **Media Releases**

- Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) VIRALEZE<sup>™</sup> distribution and supply to Vietnam - 26/10/2021
- Acrux Limited (ASX: ACR) Notice of Annual General Meeting 22/10/2021
- Clinuvel Pharmaceuticals Limited (ASX: CUV) First Patient Treated in CLINUVEL DNA Repair Study - 22/10/2021
- Neuren Pharmaceuticals Limited (ASX: NEU) Neuren receives feedback on IND for Phelan-McDermid syndrome - 21/10/2021
- Medlab Clinical Limited (ASX: MDC) Medlab signs Sale of Agreement for AUS Nutraceuticals to leading pharmacy icon, PharmaCare - 20/10/2021

#### Latest Research

 Factors Related to Small- and Mid-Capitalization Pharmaceutical Company Success Using Stock Performance as a Surrogate - By Matthew J. Ferris, Kai Sun, Corey Savard, Tejas Suresh, Mark V. Mishra

```
N0.: 29053
```

### **AUSTRALIA BIOTECHNOLOGY AND PHARMACEUTICALS**

#### **Overviews of Leading Companies**

Acrux Limited (ASX: ACR) Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) Benitec Biopharma Limited (ASX: BLT) Bionomics Limited (ASX: BNO, OTCQX: BNOEF) Clinuvel Pharmaceuticals Limited (ASX: CUV) CSL Limited (ASX: CSL) Genera Biosystems Limited IDT Australia Limited (ASX: IDT) Immutep Limited (ASX: IMM, NASDAQ: IMMP) Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA) Mayne Pharma Group Limited (ASX: MYX) Medical Developments International Limited (ASX: MVP) Medlab Clinical Limited (ASX: MDC) Mesoblast Limited (ASX: MSB; NASDAQ: MESO) MMJ Group Holdings Limited (ASX: MMJ) Monash IVF Group (ASX: MVF) Neuren Pharmaceuticals Limited (ASX: NEU) Palla Pharma Limited (ASX: PAL) Pharmaxis Limited (ASX: PXS) PolyNovo Limited (ASX: PNV) Sirtex Medical Limited Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) Viralytics Limited (NYSE: MRK) Vita Life Sciences Limited (ASX: VLS)

Senior Associate: Joseph Hang Ellision

# Are you MIFID II ready? You might like to talk to Acquisdata about our Bespoke Research offering. www.acquisdata.com/bespoke-research #

#Acquisdata is proud to be hosting a league on Estimize. Want the opportunity to win free subscriptions? Then join the Acquisdata Media and Telecommunications League at: https://www.estimize.com/leagues/acquisdata-media-and-telecommunications #

#### **Industry SnapShots**

Published by Acquisdata Pty Ltd A.C.N. 147 825 536 ISSN 2203-2738 (Electronic)

©Acquisdata Pty Ltd 2021

www.acquisdata.com

#### Disclaimer of Warranties and Liability

Due to the number of sources from which the information and services on the Acquisdata Pty Ltd Service are obtained, and the inherent hazards of electronic distribution, there may be delays, omissions or inaccuracies in such information and services. Acquisdata Pty Ltd and its affiliates, agents, sales representatives, distributors, and licensors cannot and do not warrant the accuracy, completeness, currentness, merchant ability or fitness for a particular purpose of the information or services available through the Acquisdata Pty Ltd service In no event will Acquisdata Ptv Ltd. its affiliates, agents, sales representatives, distributors or licensors be liable to licensee or anyone else for any loss or injury caused in whole or part by contingencies beyond its control in procuring, compiling, interpreting, editing, writing, reporting or delivering any information or services through the Acquisdata Ptv Ltd Service. In no event will Acquisdata Pty Ltd or its affiliates, agents, sales representatives, distributors or licensors be liable to licensee or anyone else for any decision made or action taken by licensee in reliance upon such information or services or for any consequential, special or similar damages, even if advised of the possibility of such damages. licensee agrees that the liability of Acquisdata Pty Ltd, its affiliates, agents, sales representatives, distributors and licensors, if any, arising out of any kind of legal claim (whether in contract, tort or otherwise) in any way connected with the Acquisdata Pty Ltd service shall not exceed the amount licensee paid for the use of the Acquisdata Pty Ltd service in the twelve (12) months immediately preceding the event giving rise to such claim